We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 27, 2021

Predictors of Improvement in PFS With Maintenance PARP Inhibitor Therapy in Women With Platinum-Sensitive, Recurrent Ovarian Cancer

Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancer
Molecular and Clinical Predictors of Improvement in Progression-Free Survival With Maintenance PARP Inhibitor Therapy in Women With Platinum-Sensitive, Recurrent Ovarian Cancer: A Meta-Analysis
Cancer 2021 Mar 19;[EPub Ahead of Print], CK Lee, ML Friedlander, A Tjokrowidjaja, JA Ledermann, RL Coleman, MR Mirza, UA Matulonis, E Pujade-Lauraine, R Bloomfield, S Goble, P Wang, RM Glasspool, CL Scott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading